CA3145872A1 - Compounds comprising a fibroblast activation protein ligand and use thereof - Google Patents

Compounds comprising a fibroblast activation protein ligand and use thereof Download PDF

Info

Publication number
CA3145872A1
CA3145872A1 CA3145872A CA3145872A CA3145872A1 CA 3145872 A1 CA3145872 A1 CA 3145872A1 CA 3145872 A CA3145872 A CA 3145872A CA 3145872 A CA3145872 A CA 3145872A CA 3145872 A1 CA3145872 A1 CA 3145872A1
Authority
CA
Canada
Prior art keywords
pro
cys
phe
thr
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145872A
Other languages
English (en)
French (fr)
Inventor
Frank Osterkamp
Dirk Zboralski
Eberhard Schneider
Christian Haase
Matthias Paschke
Aileen Hohne
Jan Ungewiß
Christiane Smerling
Ulrich Reineke
Anne BREDENBECK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Publication of CA3145872A1 publication Critical patent/CA3145872A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3145872A 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof Pending CA3145872A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19000325.1 2019-07-08
EP19198810.4 2019-09-20
EP19198810 2019-09-20
PCT/EP2020/069308 WO2021005131A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
CA3145872A1 true CA3145872A1 (en) 2021-01-14

Family

ID=71409440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145872A Pending CA3145872A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Country Status (12)

Country Link
US (1) US20220315554A1 (enExample)
EP (1) EP3997104A1 (enExample)
JP (2) JP7801207B2 (enExample)
KR (1) KR20220032078A (enExample)
CN (3) CN118955620A (enExample)
AU (2) AU2020309161A1 (enExample)
BR (1) BR112022000144A2 (enExample)
CA (1) CA3145872A1 (enExample)
CL (1) CL2022000016A1 (enExample)
IL (2) IL324399A (enExample)
MX (1) MX2022000251A (enExample)
WO (1) WO2021005131A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
EP4147053B1 (en) 2020-05-07 2026-01-28 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN116888138A (zh) * 2020-11-30 2023-10-13 瑞择生物公司 放射性药物缀合组合物及其用途
EP4050018A1 (en) * 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4448544A2 (en) * 2021-12-17 2024-10-23 3B Pharmaceuticals GmbH Carbonic anhydrase ix ligands
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
IL322552A (en) 2023-02-10 2025-10-01 Chengdu New Radiomedicine Tech Co Ltd Polypeptide compound and its use
JP2026510608A (ja) 2023-02-14 2026-04-08 ラーディオファックス ゲーエムベーハー 薬物及び処置の方法
CN118754936A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
EP4692105A1 (en) * 2023-03-27 2026-02-11 Bivision Pharmaceuticals, Inc Cyclic polypeptide compound and use thereof
CN118754937A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
CN118930606A (zh) * 2023-05-11 2024-11-12 成都纽瑞特医疗科技股份有限公司 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用
TW202502800A (zh) * 2023-07-11 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種成纖維細胞活化蛋白配體及其用途
AU2024334645A1 (en) * 2023-08-31 2026-02-26 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides
AU2025214491A1 (en) 2024-02-01 2026-08-06 Novartis Ag Methods for treating cancer
WO2026008525A1 (en) * 2024-07-01 2026-01-08 Bayer Aktiengesellschaft Stable radionuclide-containing formulations
WO2026017046A1 (zh) * 2024-07-19 2026-01-22 晶核生物医药科技(南京)有限公司 一种环多肽、其制备方法和应用
WO2026021314A1 (zh) * 2024-07-22 2026-01-29 山东威智知科药业有限公司 Fap化合物及其用途
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途
WO2026046340A1 (zh) * 2024-08-30 2026-03-05 江苏恒瑞医药股份有限公司 一种f-18标记反应前体分子的方法
WO2026056964A1 (zh) * 2024-09-14 2026-03-19 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
WO2026149506A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种药物组合物及其制备方法
WO2026149529A1 (zh) * 2025-01-10 2026-07-16 天津恒瑞医药有限公司 一种成纤维细胞活化蛋白配体及其用途
WO2026163110A1 (en) 2025-01-30 2026-08-06 Novartis Ag Combinations with fap targeting compounds and conjugates thereof
CN120590466B (zh) * 2025-08-06 2026-05-12 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2401252A1 (en) 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
CA2681351A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
CN102203061A (zh) 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
BR112014022435B1 (pt) * 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
US11236123B2 (en) * 2016-01-20 2022-02-01 Polypeptide Laboratories Holding (Ppl) Ab Method for preparation of peptides with psWang linker
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
CN105949282B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
CN106046121B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
PL3997103T3 (pl) * 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie

Also Published As

Publication number Publication date
WO2021005131A1 (en) 2021-01-14
MX2022000251A (es) 2022-02-21
JP7801207B2 (ja) 2026-01-16
CN114341158A (zh) 2022-04-12
AU2020309161A1 (en) 2022-01-27
EP3997104A1 (en) 2022-05-18
IL289673B1 (en) 2025-12-01
AU2026202638A1 (en) 2026-05-21
IL324399A (en) 2026-01-01
CN118930608A (zh) 2024-11-12
CN118955620A (zh) 2024-11-15
IL289673B2 (en) 2026-04-01
IL289673A (en) 2022-03-01
JP2022541752A (ja) 2022-09-27
BR112022000144A2 (pt) 2022-02-22
CL2022000016A1 (es) 2022-08-19
KR20220032078A (ko) 2022-03-15
JP2026062901A (ja) 2026-04-10
CN114341158B (zh) 2024-08-06
US20220315554A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP2021130672A (ja) Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
CA2452923C (en) Peptide-based compounds for targeting integrin receptors
KR102498607B1 (ko) 방사성표지 ｈｅｒ２ 결합 펩티드
ES2311703T3 (es) Peptidos y peptidomimeticos que tienen actividad anti-proliferativa y/o que aumentan agentes o tratamientos que dañan los acidos nucleicos.
JP2021506910A (ja) ＥｐｈＡ２に特異的な二環ペプチドリガンド
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
AU2019469641B2 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
JP2025513489A (ja) Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
IL301342A (en) Novel CXCR4-targeting compounds
KR20140012112A (ko) 테크네튬 표지화 펩티드
IL324842A (en) Dll3 targeting peptides and constructs thereof
ES2676184T3 (es) Composición para su uso en un método para la selección de cánceres
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
TW202542178A (zh) 靶向生長抑制素受體２之放射性藥物及其用途
HK40130456A (en) Bi-ligand drug conjugate and use thereof

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240812

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240911

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250319

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20260629

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260715

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260715